WO2023186536A1 - Composition de protection de l'œil - Google Patents

Composition de protection de l'œil Download PDF

Info

Publication number
WO2023186536A1
WO2023186536A1 PCT/EP2023/056569 EP2023056569W WO2023186536A1 WO 2023186536 A1 WO2023186536 A1 WO 2023186536A1 EP 2023056569 W EP2023056569 W EP 2023056569W WO 2023186536 A1 WO2023186536 A1 WO 2023186536A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
zeaxanthin
lutein
combination
weight
Prior art date
Application number
PCT/EP2023/056569
Other languages
German (de)
English (en)
Inventor
Olaf Hülsmann
Original Assignee
Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102022110581.4A external-priority patent/DE102022110581A1/de
Application filed by Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh filed Critical Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh
Priority to EP23712476.3A priority Critical patent/EP4432857A1/fr
Publication of WO2023186536A1 publication Critical patent/WO2023186536A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Definitions

  • composition to protect the eye Composition to protect the eye
  • the present invention relates to the technical (i.e. medical pharmaceutical or food technology) field of the negative influence or negative effect of blue light in particular on eye health, in particular in relation to the human eye, as well as on sleep behavior or the day/night rhythm .
  • the present invention relates in particular to the field of preventive treatment or prophylaxis on the one hand and therapeutic treatment on the other hand of light-induced, in particular blue light-induced, impairment and/or damage to eye health or the human eye, in particular both in the medical field -pharmaceutical sector as well as in the non-medical sector or in the field of food and food technology.
  • the present invention relates in particular to the field of preventive treatment or prophylaxis on the one hand and the therapeutic treatment on the other hand of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by or related to blue light in particular Rhythm both in the medical or medical-pharmaceutical sector as well as in the non-medical sector or in the field of food or food technology.
  • the present invention relates in particular to a composition, in particular for oral administration, preferably for eye health or preferably for reducing negative effects of, in particular, blue light on the human eye.
  • the present invention also relates to a related dietary supplement on the one hand and to a drug, pharmaceutical, medical product or homeopathic drug on the other hand or, in addition, also to a related dosage or application form based on the composition according to the invention.
  • the present invention also relates to a composition for use in the prophylactic or therapeutic medical treatment of diseases or irritations or disorders or damage to the human eye caused by or associated with blue light in particular.
  • the present invention also relates to the use of the composition according to the invention (for the production of a medicament) for the prophylactic or therapeutic medical treatment of the above-mentioned conditions or indications.
  • the present invention also relates to a composition for use in the prophylactic or therapeutic medical treatment of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by, or associated with, blue light.
  • the present invention also relates to a corresponding use as such of the composition according to the invention.
  • the present invention also relates to a corresponding drug, pharmaceutical, medical device or homeopathic medicine or a dosage form for use in the prophylactic or therapeutic medical treatment of illnesses or irritations or disorders caused or related by, in particular, blue light .Damage to the human eye or a corresponding use as such of the drug, pharmaceutical, medical device or homeopathic in question.
  • the present invention also relates to a drug, pharmaceutical, medical device or homeopathic medicine or a related dosage form for use in the prophylactic or therapeutic medical treatment of sleep disorders or dysregulation of the natural day caused by, in particular, blue light or related thereto /night rhythm or circadian rhythm and related use as such.
  • the present invention also relates to the combination according to the invention of (a) lutein and (b) zeaxanthin for use in the prophylactic or therapeutic medical treatment of diseases or irritations or disorders or damage caused or related by, in particular, blue light of the human eye as well as the related use of the combination in question (for the production of a medicinal product) for the prophylactic or therapeutic medical treatment of the previously listed conditions or indications.
  • the combination also relates to the combination according to the invention of (a) lutein and (b) zeaxanthin for use in the prophylactic or therapeutic medical treatment of sleep disorders or dysregulation of the natural day/day caused by or associated with blue light in particular. Night rhythm or circadian rhythm as well as a corresponding use as such.
  • the present invention also relates to the use of the composition according to the invention for non-medical treatment, in particular for prophylactic non-medical treatment, of diseases or irritations or disorders or damage to the human eye caused by or related to blue light in particular, as well as the relevant use of the dietary supplement according to the invention or the dosage form according to the invention based on the composition according to the invention.
  • the present invention also relates to the use of the composition according to the invention for the non-medical treatment of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by, or associated with, blue light.
  • the present invention also relates to the related use of the foodstuff according to the invention or the dosage form according to the invention.
  • the present invention also relates to the use of a combination of (a) lutein and (b) zeaxanthin for the non-medical treatment, in particular for the prophylactic non-medical treatment, of diseases or irritations or disorders caused by, in particular, blue light or related thereto. Damage to the human eye.
  • the present invention also relates to the use of a combination of (a) lutein and (b) zeaxanthin for the non-medical treatment of sleep disorders or dysregulation of the natural day/night rhythm caused by or related to blue light in particular. of the circadian rhythm.
  • the present invention also relates to a method for the prophylactic or therapeutic medical treatment of diseases or irritations or disorders or damage to the human eye caused by or associated with blue light in particular.
  • the present invention also relates to a method for prophylactic or therapeutic medical treatment caused by, in particular, blue light-related sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm.
  • the present invention also relates to a related method for the non-medical, in particular for the prophylactic, non-medical treatment of diseases or irritations or disorders or damage to the human eye caused by or related to blue light in particular.
  • the present invention also relates to a method for the non-medical treatment of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by, or associated with, blue light.
  • the present invention also relates to a kit (kit-of-parts) based on spatially separate and functionally related components, at least one of the aforementioned components having or consisting of the composition according to the invention.
  • LED Light Emitting Diode
  • a mixture of light of different wavelengths or wavelength ranges is used, for example using blue light or yellow light or the like, in particular blue Light can have a negative impact on eye health.
  • blue Light Due to the increasing spread of corresponding display devices or displays as well as the increasing use of LED lighting, accompanied by a changed spectral light composition compared to natural light with an increased proportion of blue light, as well as due to the changed visual and work behavior, the exposure to blue light is increasing that the human eye is more exposed to blue light than before, and this is increasing.
  • LED-based lamps are also used, particularly against the background of increased energy efficiency.
  • LEDs are used in particular to generate light and/or color, for example from computers, laptops, tablets, smartphones and the like, sometimes produce intense blue light.
  • LED lamps also have stronger radiation in the underlying wave range of blue light than conventional light bulbs.
  • the introduction of energy-saving lighting and the widespread use of modern computer and mobile technologies have consequently changed the light exposure of the human eye, with increased exposure to blue light in particular. this is also valid against the background that there is often intensive use of corresponding electronic devices or a long stay in rooms that are artificially lit or with the use of LED light sources, both in private and professional or work areas.
  • Blue light generally has a wavelength range of approximately 380 nm to approximately 500 nm and represents a component of the electromagnetic radiation that can be perceived by the eye. Blue light is therefore part of the visible part of the light spectrum. Blue light can in particular also include the so-called HEV light (high energy visible light), which can generally have a wavelength in the range from 400 nm to 460 nm.
  • HEV light high energy visible light
  • Blue light with the wavelengths present is generally considered to have a negative influence or potential for damage to the human eye, with blue light in particular in the wavelength range from approximately 380 nm to approximately 500 nm and in particular from approximately 410 nm to approximately 455 nm or up to approximately 450 nm is particularly important with regard to negative influence or damage to eye health.
  • the rear section of the eye in particular, specifically the retina with the associated cellular structures, such as visual cells, can be affected by excessive exposure to blue light.
  • the retina forms the inner layer of the eyeball and is a very thin and easily tearable skin, which is filled with light-sensitive cells (photoreceptors), namely rods and cones. Is provided.
  • the point of sharpest vision (fovea or yellow spot) and the exit point of the optic nerve are located in the rear area of the retina.
  • the retina is a complex and sensitive biological structure that can be negatively affected or damaged by excessive exposure to blue light.
  • a negative influence on the retina or on visual cells is assumed due to a direct influence of high-energy light on the tissue and as a result of the formation of oxygen radicals induced by blue light with associated cell damage.
  • An impairment of visual cells is also problematic because dead or lost visual cells can no longer be replaced by the body's own regeneration processes, so that irreversible damage can result, accompanied by a possible impairment of vision.
  • the exposure of the retina to blue light and the associated dangers can be increased, particularly in poor lighting conditions, such as high (ambient) darkness, since under these conditions the pupil of the eye is dilated, so that more light is captured or in the eye occurs, also with regard to the underlying harmful blue light component. This is also why working on a computer or tablet or the like can be unfavorable in poor lighting conditions due to the high proportion of blue light and large pupil openings.
  • blue light inhibits or reduces the production or release of the sleep hormone melatonin, so excessive exposure to blue light can also lead to sleep disorders or an influence on the circadian rhythm or the day/night rhythm .
  • the prior art also lacks tailoring or optimization with regard to reducing the negative or damaging influence of, in particular, blue light of a certain wavelength range, as is the case in particular with LED-based display devices or displays as well as LED lamps. So that the previous approaches do not always do justice to current and future developments with increasing exposure to blue light, especially with a special wavelength range.
  • the prior art also mentions the use of special carotenoids with regard to eye diseases (see WO 2013/041935 A1).
  • one object of the present invention is to provide an efficient concept or related compositions and active ingredients which are at least largely able to avoid or at least mitigate the previously described disadvantages of the prior art.
  • a further object of the invention is to provide a corresponding concept or related compositions and active ingredients which, when used or applied, have a protective function with regard to eye health or the human eye, in particular against the harmful or disadvantageous effects of blue light in particular, in particular both compared to (blue) light originating from LED light sources and compared to display devices or displays corresponding in particular to blue light.
  • a yet further object of the present invention can be seen in particular in the fact that corresponding concepts, compositions or active ingredients are to be provided, with the help of which diseases or irritations or disorders caused in particular by blue light in particular or associated therewith. Damage to the human eye is counteracted, both on a prophylactic or preventative as well as on a therapeutic level.
  • a related object of the present invention can also be seen in the fact that, on the basis of the present invention, sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by blue light in particular or related thereto are counteracted .
  • a further object of the present invention can also be seen in enabling a correspondingly large variety or a large spectrum of possible dosage or dosage forms of the composition provided according to the invention, in order to thereby enable a correspondingly broad area of application or application.
  • the composition according to the invention should be able to be used both in the medical-therapeutic area and in the food technology area.
  • the present invention therefore proposes - according to a first aspect of the present invention - a composition, in particular for oral administration, preferably for eye health or for reducing negative effects of, in particular, blue light in relation to the human eye, whereby the composition has a combination of (a) lutein and (b) zeaxanthin in a specific lutein/zeaxanthin weight ratio, according to claim 1.
  • a composition in particular for oral administration, preferably for eye health or for reducing negative effects of, in particular, blue light in relation to the human eye
  • the composition has a combination of (a) lutein and (b) zeaxanthin in a specific lutein/zeaxanthin weight ratio, according to claim 1.
  • the present invention also relates to a dietary supplement according to the relevant independent claim and also to a corresponding medicine, pharmaceutical, medical device or homeopathic according to the respective relevant and dependent claims and also to a dosage form (Application form) according to the relevant independent claim.
  • a dietary supplement according to the relevant independent claim and also to a corresponding medicine, pharmaceutical, medical device or homeopathic according to the respective relevant and dependent claims and also to a dosage form (Application form) according to the relevant independent claim.
  • a further subject of the present invention - according to a second aspect of the present invention - is also the composition according to the invention for use in the prophylactic or therapeutic medical treatment of illnesses or irritations or disorders caused by, or associated with, blue light in particular. Damage to the human eye according to the relevant independent claim.
  • the present invention also relates to the related use of the composition as such.
  • the present invention also relates to the composition according to the invention for use in the prophylactic or therapeutic medical treatment of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by, or associated with, blue light in accordance with the relevant independent claim.
  • the present invention also relates to the corresponding use of the composition according to the relevant independent claim.
  • the present invention also relates to the relevant drugs, pharmaceuticals, medical devices or homeopathics or the dosage forms according to the invention, each for use in the prophylactic or therapeutic medical treatment of the above-mentioned conditions or indications, as well as the related uses as such as defined in the respective independent claims.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • the subject of the present invention - according to a third aspect of the present invention - is also the combination according to the invention of (a) lutein and (b) zeaxanthin for use in the prophylactic or therapeutic treatment of diseases caused by, in particular, blue light or related thereto Illnesses or irritations or Disturbances or damage to the human eye and the related use as such.
  • the present invention also relates to the combination in question for use in the prophylactic or therapeutic medical treatment of sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by or associated with blue light Rhythm or the related use as such.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • the present invention relates - according to a fourth aspect of the present invention - to the uses of the composition according to the present invention for the non-medical treatment of diseases or irritations or disorders or damage to the human body caused by or associated with blue light in particular Eye on the one hand or for the non-medical treatment of sleep disorders caused or related to blue light or dysregulation of the natural day/night rhythm or the circadian rhythm.
  • the invention also relates to the uses of the food according to the invention or the dosage form according to the invention according to the independent claims relating to these subjects of the present aspect.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • Another subject of the present invention - according to a fifth aspect of the present invention is the use of the combination of (a) lutein and (b) zeaxanthin according to the invention for the non-medical treatment of the previously mentioned diseases or irritations or disorders or damages on the one hand or .for the non-medical treatment of the previously mentioned sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm, as defined in the respective independent claims.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • Another subject of the invention - according to a sixth aspect of the present invention - are also the methods according to the invention, namely, on the one hand, for the prophylactic or therapeutic medical treatment of the previously mentioned diseases or irritations or disorders or damage to the human eye or, on the other hand, of the previously mentioned listed sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm, as defined in the respective independent claims.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • another subject of the present invention - according to a seventh aspect of the present invention - are the respective methods according to the invention for non-medical treatment, namely on the one hand with regard to the previously mentioned diseases or irritations or disorders or damage to the human eye and on the other hand, with regard to the previously mentioned sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm, as defined in the respective independent claims.
  • Advantageous developments and refinements of this aspect of the invention are the subject of the relevant subclaims.
  • kits-of-parts are also the subject matter of the present invention - according to an eighth aspect of the present invention -.
  • the composition according to the invention can be present in numerous forms, for example in the form of a drug, pharmaceutical, medical device or homeopathic, and on the other hand in the form of a food supplement, cosmetic or in the form of an article of use.
  • the composition according to the invention can also be present as or in an underlying dosage form, such as a tablet, capsule, in particular soft capsule, or the like.
  • the composition can therefore not only be in the form of medicines or pharmaceuticals as such (ie in terms of pharmaceutical law) or be present as a component thereof, but also in the form of medical products and, beyond that, homeopathic products and nutritional supplements as well as cosmetics and everyday items be trained or act as part of it.
  • food supplement as used in the context of the present invention is to be understood very broadly and in particular includes not only food supplements as such, but also other foods or foods, in particular fortified foods (such as cereals, dairy products, Juices, etc.) as well as balanced diets (also called Food for Special Medical Purposes or FSMPs).
  • the subject of the present invention - according to a first aspect of the present invention - is therefore the composition according to the invention, in particular for oral administration, preferably for eye health or preferably for reducing negative effects of, in particular, blue light in relation to the human eye, the composition being a Combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically or food-technically effective amounts, the combination of (a) lutein and (b) zeaxanthin having a lutein/zeaxanthin weight ratio ⁇ 1: 1, in particular in the range from 1: 4 to 1: 9.75.
  • a special feature of the present invention can therefore be seen in particular in the fact that the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1 (ie less than 1 or less than 1), in particular ⁇ 1:1. 2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6 (in particular, however, with the proviso that a lutein/zeaxanthin weight ratio of 1:50, in particular of 1:20, should not be fallen below).
  • the combination of (a) lutein and (b) Zeaxanthin has a lutein/zeaxanthin weight ratio in the range of ⁇ 1:1 to 1:50 or in the range of ⁇ 1:1 to 1:20.
  • the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9 , preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1: 6 to 1: 8.8.
  • the special composition according to the invention is based on a combination of the active substances (a) lutein on the one hand and (b) zeaxanthin on the other hand with a special lutein / zeaxanthin weight ratio, according to which, according to the invention, in functional and In a targeted manner, proportionately more zeaxanthin is used than lutein (i.e.
  • the composition has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75), especially when administered (per-)orally or absorption of the composition in an unexpected and surprising and efficient manner enables a protective function against, in particular, blue light with regard to eye health or the human eye.
  • sleep disorders or dysregulation of the natural day/night rhythm or the circadian rhythm caused by or related to blue light in particular can also be positively influenced in an unexpected way.
  • composition according to the invention particularly based on the composition according to the invention or the relevant special combination of (a) lutein and (b) zeaxanthin with a very specific lutein/zeaxanthin weight ratio, a reduction or reduction of negative effects of blue light in particular on eye health is achieved or for the human eye and for sleep health.
  • a high protective function against, in particular, blue light with a specific wavelength range is made possible, in particular in a surprising manner, as is emitted or emitted in particular by LED light sources, such as LED lamps.
  • LED light sources such as LED lamps.
  • special protection is also provided against blue light in particular, as is the case, for example, in particular LED-based display devices, such as television, computer, mobile phone, laptop or tablet display devices or technical displays.
  • composition according to the invention is therefore particularly suitable for the treatment of diseases or irritations or disorders or damage to the human eye caused by, or associated with, blue light or in general for promoting or protecting eye health .
  • compositions according to the invention are applied, in particular (per-)oral application or systemic absorption, an accumulation or enrichment or the presence of the Substances in the eye tissue or in and/or on the retina result, so that on this basis the protective function or the protective properties against blue light are present or can be caused directly at the site of action.
  • the combination of (a) lutein on the one hand and (b) zeaxanthin on the other hand in the special lutein/zeaxanthin weight ratios specified according to the invention leads to a particularly effective absorption of blue light in particular, both in the general wavelength range of blue Light and especially in the range of wavelengths of blue light, which is particularly produced by LEDs Light sources are emitted, so that overall a particularly efficient protective function is enabled.
  • composition according to the invention also has good tolerability overall, especially since the active substances used based on (a) lutein or (b) zeaxanthin represent natural substances, namely carotenoids, such as can be obtained or isolated, for example, from corresponding plant material.
  • composition according to the invention can also be seen in the fact that it is present or can be provided in numerous dosage forms, so that there are numerous application options which can be optimized or selected depending on the application and individual case.
  • a further advantage of the concept according to the invention can also be seen in the fact that a causal and, so to speak, approach directly related to the blue light itself in particular is provided, according to which, due to the excellent absorption properties of the special combination of (a) lutein and (b) zeaxanthin with the With a defined lutein/zeaxanthin weight ratio, blue light in particular is intercepted or rendered harmless before it reaches the site of action, so that related (subsequent) symptoms do not even occur or are reduced or prevented from the outset.
  • composition according to the invention can also be further tailored and the underlying active profile can be further adjusted.
  • positive substances such as special vitamins, minerals, salts or the like, can be used, particularly with regard to eye health, which, in conjunction with lutein or zeaxanthin, lead to further protection or a sustainable improvement in eye health as part of a holistic effect concept can.
  • the composition according to the invention can be further tailored.
  • the additional use of melatonin or serotonin can be mentioned, as explained below, whereby the aforementioned active substances in interaction with the combination of lutein and zeaxanthin on which the composition according to the invention is based lead to further improved properties with regard to the aforementioned conditions or indications .
  • composition according to the invention a very specific combination of (a) lutein on the one hand and (b) zeaxanthin on the other hand is used, and this in particular with a very specific lutein/zeaxanthin weight ratio, namely ⁇ 1: 1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6, or in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1:8.8.
  • a very specific lutein/zeaxanthin weight ratio namely ⁇ 1: 1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1
  • compositions according to the invention are characterized in this context by excellent absorption behavior.
  • the active substances used according to the invention in the form of (a) lutein on the one hand and (b) zeaxanthin on the other hand are each very specific representatives from the substance classes of xanthophylls or carotenoids.
  • the lutein used according to the invention is, in particular with regard to the pure substance, (3R, 3'R, 6'R)-ß,E-carotene-3,3-diol.
  • Lutein is generally an orange-yellow xantophyll and, along with ß-carotene and lycopene, is one of the most common carotenoids.
  • the lutein can be present as a pure substance or in the form of its esters, salts or hydrates, preferably esters. According to the invention, however, it is preferred that the lutein is present or used as a pure substance.
  • the zeaxanthin used according to the invention is (3R,3'R)-ß,ß-carotene-3,3'-diol, particularly with regard to the pure substance.
  • the zeaxanthin used according to the invention in the context of the present invention it can behave in particular in such a way that (b) the zeaxanthin is present as a pure substance or in the form of its esters, salts or hydrates, preferably esters.
  • the zeaxanthin is present or used as a pure substance.
  • the zeaxanthin is in the form of its isomers, in particular in the form of a mixture of at least two isomers, preferably in the form of (3R, 3'R)-zeaxanthin, (3S, 3'S)-zeaxanthin and/or meso-zeaxanthin, preferably (3R, 3'R)-zeaxanthin and/or meso-zeaxanthin, is present.
  • the lutein and/or (b) the zeaxanthin in particular independently of one another, is or are of natural and/or non-animal, in particular of plant origin and/or algae-based origin. Furthermore, according to the invention, it can behave in such a way that (a) the lutein and/or (b) the zeaxanthin, in particular independently from each other, in the form of at least one plant and/or algae component and/or at least one plant and/or algae ingredient and/or at least one plant and/or algae extract, preferably at least one plant and/or algae extract, is present and/or used is or are. In this way, good tolerability can be ensured while at the same time being highly effective.
  • the lutein and/or (b) the zeaxanthin, in particular independently of one another can be of fermentative origin or can (a) the lutein and/or (b) the zeaxanthin, in particular independently of one another, be obtained by fermentation. This can also ensure a high level of purity.
  • the composition has the following lutein/zeaxanthin weight ratios.
  • the applicant has surprisingly found that the weight ratios listed below are associated with particularly good absorption behavior towards, in particular, blue light, including in relation to light emitted by LED light sources.
  • the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5 , very particularly preferably ⁇ 1:6, or that the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, most preferably in the range from 1:6 to 1:8.8 .
  • the composition contains the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range from 0.1% by weight to 90% by weight, in particular in the range from 0.5% by weight .-% to 80% by weight, preferably in the range from 1% by weight to 70% by weight, preferably in the range from 2% by weight to 60% by weight, particularly preferably in the range from 3% by weight. -% to 55% by weight, very particularly preferably in the range from 5% by weight to 50% by weight, based on the composition.
  • the following weight-related amounts of the combination of (a) lutein and (b) zeaxanthin with the relevant lutein/zeaxanthin weight ratios can be present in the composition according to the invention:
  • the composition can contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range from 0.1% by weight to 90% by weight, in particular in the range from 0.5% by weight to 80% by weight, preferably in the range from 1% by weight to 70% by weight, preferably in the range from 2% by weight to 60% by weight, particularly preferably in the range from 3% by weight to 55% by weight % by weight, very particularly preferably in the range from 5% by weight to 50% by weight, based on the composition; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or where the combination of
  • composition can contain the combination of (a) lutein and
  • (b) contain zeaxanthin in an amount ranging from 0.1% to 90% by weight based on the composition; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1: 8.8.
  • the composition contains the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range from 0.5% by weight to 80% by weight, based on the composition, contains; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly particularly
  • the composition contains the combination of (a) lutein and (b) zeaxanthin in a weight-based amount in the range from 1% by weight to 70% by weight, based on the composition; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in
  • the composition contains the combination of (a) lutein and (b) zeaxanthin in a weight-based amount in the range from 2% by weight to 60% by weight, based on the composition ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly
  • the composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight ranging from 3% to 55% by weight, based on the composition; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1: 8.8
  • the composition may contain the combination of lutein and zeaxanthin in an amount by weight in the range of 5% by weight to 50% by weight, based on the composition; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1
  • composition according to the invention can also have the following specific weight-based amounts of the combination of (a) lutein and (b) zeaxanthin with the relevant lutein/zeaxanthin weight ratios. Also the following quantities or Conditions go hand in hand with particularly good properties of the composition according to the invention:
  • the composition contains the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range from 0.1% by weight to 90% by weight, based on the composition, wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1 and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1 : 4 to 1: 9.75.
  • the composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range of 0.5% by weight to 80% by weight, based on the composition, the combination of (a ) Lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:2 and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9 having.
  • the composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range of
  • composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range of
  • the composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range of 3% by weight to 55% by weight, based on the composition, the combination of (a) lutein and (b) zeaxanthin a lutein/zeaxanthin Weight ratio ⁇ 1:5 and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:6 to 1:8.99.
  • the composition may contain the combination of (a) lutein and (b) zeaxanthin in an amount by weight in the range of 5% by weight to 50% by weight, based on the composition, the combination of (a) Lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:6 and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:6 to 1:8, 8 has.
  • compositions Based on the aforementioned combinations of features with regard to the weight-related amounts of the combination of (a) lutein and (b) zeaxanthin with the relevant special lutein/zeaxanthin weight ratio, particularly efficient or effective compositions can be provided.
  • composition according to the invention can be equipped with further ingredients or active components in a targeted and purposeful manner.
  • further tailoring or adjustment of the active properties of the composition according to the invention can also be carried out with regard to the respective use or application:
  • the composition contains at least one substance that influences the day/night rhythm and/or has a sleep-active and/or sedative and/or calming or sleep-promoting substance, in particular melatonin and/or serotonin. This can have a positive influence on sleep behavior and the day/night rhythm in particular.
  • the composition can contain at least one substance that influences the day/night rhythm and/or sleep-active substance, in particular melatonin and/or serotonin, in particular each and/or independently of one another, in a weight-related amount in the range from 0.05% by weight to 20% by weight, in particular in the range from 0.1% by weight to 15% by weight, preferably in the range from 0.5% by weight to 10% by weight, preferably in the range from 1% by weight % to 5% by weight, based on the composition.
  • This can also counteract a sleep disorder or dysregulation of the day/night rhythm or circadian rhythm caused by or related to blue light in particular.
  • the measure according to the invention with the use of melatonin or serotonin can counteract a reduction in the production or release of the body's own melatonin caused by, or associated with, blue light, or a corresponding reduction can be compensated for.
  • a reduction in the production or release of the body's own melatonin caused by, or associated with, blue light or a corresponding reduction can be compensated for.
  • sleep behavior and the day/night rhythm can also be improved or specifically regulated, as mentioned above.
  • melatonin and/or serotonin are present in pure form, in particular independently of one another.
  • melatonin or serotonin in particular independently of one another, is present in the form of a respective derivative or precursor.
  • it can be tryptophan, for example.
  • tryptophan is preferably L-tryptophan.
  • the composition contains at least one drug (plant or herb) which influences the day/night rhythm and/or sleep-active and/or sedative and/or calming and/or sleep-inducing drug (plant or herb), in particular selected from the group of Valerian, hops, St. John's wort, lavender, lemon balm, passionflower, chamomile, cranberry, walnut, pistachio and Montmorency sour cherry as well as their combinations and mixtures.
  • at least one drug plant or herb which influences the day/night rhythm and/or sleep-active and/or sedative and/or calming and/or sleep-inducing drug (plant or herb), in particular selected from the group of Valerian, hops, St. John's wort, lavender, lemon balm, passionflower, chamomile, cranberry, walnut, pistachio and Montmorency sour cherry as well as their combinations and mixtures.
  • the composition can contain at least one drug (plant or herb) that influences the day/night rhythm and/or sleep-active and/or sedative and/or calming and/or sleep-inducing drug, in particular each and/or independently of one another, in a weight-related amount in the range from 0.1% by weight to 25% by weight, in particular in the range from 0.2% by weight to 20% by weight, preferably in the range from 0.5% by weight to 15% by weight. -%, preferably in the range from 1% by weight to 10% by weight, based on the composition.
  • at least one drug plant or herb
  • the composition can contain at least one drug (plant or herb) that influences the day/night rhythm and/or sleep-active and/or sedative and/or calming and/or sleep-inducing drug, in particular each and/or independently of one another, in a weight-related amount in the range from 0.1% by weight to 25% by weight, in particular in the range from 0.2% by weight to 20% by weight, preferably in the range from 0.5% by weight to 15% by weight.
  • the at least one drug influencing the day/night rhythm and/or sleep-active and/or sedative and/or calming and/or sleep-promoting drug in particular independently of one another, in the form of at least one plant component and/or plant ingredient and/or plant extract, preferably Plant extract, preferably dried plant extract, may be present or used.
  • the composition can contain at least one vitamin.
  • the vitamins in question can further promote eye health in particular.
  • the vitamins listed can improve overall physical condition, which also has a positive influence on sleep behavior and the day/night rhythm.
  • the vitamin can in particular be selected from the group of vitamin A, vitamins of the B group, in particular vitamin Be, vitamin Bg and/or vitamin B12, vitamin C, vitamins of the D group, in particular vitamin D2 and/or vitamin D3, Vitamin E, vitamins of the K group, in particular vitamin K1 and/or vitamin K2, as well as their combinations and mixtures.
  • the vitamin can preferably be selected from the group of vitamin A, vitamins of the B group, in particular vitamin Be, vitamin B9 and/or vitamin B12, and vitamin C and combinations and mixtures thereof.
  • the vitamin can preferably be selected from the group of vitamin A and vitamins of the B group, in particular vitamin Be, vitamin B9 and/or vitamin B12, as well as combinations and mixtures thereof.
  • the composition can contain the at least one vitamin, in particular each and/or independently of one another, in a weight-based amount in the range from 0.1% by weight to 60% by weight, in particular in the range from 0.2% by weight. % to 50% by weight, preferably in the range from 0.5% by weight to 40% by weight, preferably in the range from 0.75% by weight to 20% by weight, particularly preferably in the range from 1 % by weight to 10% by weight, based on the composition.
  • the at least one vitamin can be present, in particular independently of one another, in pure form and/or in the form of a derivative.
  • the composition can contain at least one zinc component or zinc compound, preferably zinc salt.
  • the zinc component can in particular be selected from the group of zinc oxide, Zinc gluconate, zinc orotate, zinc sulfate, zinc citrate, zinc acetate, zinc L-ascorbate, zinc L-aspertate, zinc bisglycinate, zinc chloride, zinc lactate, zinc L-lysinate, zinc malate, zinc mono-L-methionine sulfate, zinc carbonate, zinc L- pidolate and zinc sulfate and their combinations and mixtures, preferably selected from the group of zinc oxide, zinc gluconate, zinc orotate, zinc chloride, zinc sulfate and zinc citrate and their combinations and mixtures, preferably selected from the group of zinc oxide, zinc gluconate, zinc chloride, zinc sulfate and zinc citrate and their combinations and mixtures, particularly preferably zinc oxide.
  • the composition can contain the at least one zinc component and/or zinc compound, preferably the zinc salt, in particular each and/or independently of one another, in a weight-based amount in the range from 0.5% by weight to 50% by weight, in particular in Range from 1% by weight to 40% by weight, preferably in the range from 2% by weight to 30% by weight.
  • the composition can contain a combination of vitamin A and at least one zinc component and/or zinc compound, preferably zinc salt, in particular selected from the group of zinc oxide, zinc gluconate, zinc orotate, zinc sulfate, zinc citrate, zinc acetate, zinc L-ascorbate, Zinc L-aspertate, zinc bisglycinate, zinc chloride, zinc lactate, zinc L-lysinate, zinc malate, zinc mono-L-methionine sulfate, zinc carbonate, zinc L-pidolate and zinc sulfate and their combinations and mixtures, preferably selected from the group of zinc oxide , zinc gluconate, zinc orotate, zinc chloride, zinc sulfate and zinc citrate and their combinations and mixtures, preferably selected from the group of zinc oxide, zinc gluconate, zinc chloride, zinc sulfate and zinc citrate and their combinations and mixtures, particularly preferably zinc oxide.
  • zinc salt in particular selected from the group of zinc oxide, zinc gluconate, zinc or
  • the vitamin A can be present in pure form or in the form of a derivative.
  • the composition according to the invention has this combination in a defined weight ratio.
  • the combination of vitamin A and zinc component or zinc compound, preferably zinc salt has a vitamin A/zinc component weight ratio Range from 10:1 to 1:10, preferably in the range from 5:1 to 1:4, preferably in the range from 2:1 to 1:3, particularly preferably in the range from 1:1 to 1:2.
  • the composition according to the invention can contain the combination of vitamin A and zinc component and/or zinc compound, preferably zinc salt, in an amount by weight in the range from 0.1% by weight to 60% by weight, in particular in the range from 0 .2% by weight to 50% by weight, preferably in the range from 0.5% by weight to 40% by weight, preferably in the range from 0.75% by weight to 25% by weight, especially preferably contained in the range from 1% by weight to 20% by weight, based on the composition.
  • the combination of vitamin A and zinc component and/or zinc compound, preferably zinc salt in an amount by weight in the range from 0.1% by weight to 60% by weight, in particular in the range from 0 .2% by weight to 50% by weight, preferably in the range from 0.5% by weight to 40% by weight, preferably in the range from 0.75% by weight to 25% by weight, especially preferably contained in the range from 1% by weight to 20% by weight, based on the composition.
  • vitamin A has an important function in ensuring high visual acuity as well as color perception and contrast vision.
  • the targeted use of a zinc component improves the absorption of vitamin A.
  • the zinc component is important with regard to the metabolism of the retina or retina, also with regard to providing oxidation protection or preventing oxidation damage to the retina.
  • the protective function of the composition according to the invention can be further optimized, particularly with regard to the human eye or eye health.
  • the composition according to the invention may contain lactoferrin.
  • the composition may contain lactoferrin in an amount by weight in the range of 0.1% by weight to 50% by weight, in particular in the range of 0.5% by weight to 40% by weight, preferably in the range of 1 % by weight to 30% by weight, preferably in the range from 2% by weight to 25% by weight, based on the composition.
  • the lactoferrin can be present in particular in pure form or in the form of a derivative.
  • the lactoferrin can in particular have antibacterial properties. From a physiological point of view, lactoferrin is a natural component of tears.
  • lactoferrin in the According to the composition of the invention, the relevant properties can be specifically improved or supported.
  • the protective effect of the combination of (a) lutein and (b) zeaxanthin on which the composition according to the invention is based can be supported.
  • composition according to the invention can contain at least one unsaturated fatty acid, in particular at least one polyunsaturated fatty acid, preferably at least one omega fatty acid, preferably omega-3 fatty acid, in particular selected from the group of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and alpha-linolenic acid and combinations and mixtures thereof, preferably alpha-linolenic acid, and / or preferably at least one omega-6 fatty acid, preferably linoleic acid.
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • alpha-linolenic acid alpha-linolenic acid
  • combinations and mixtures thereof preferably alpha-linolenic acid, and / or preferably at least one omega-6 fatty acid
  • the composition according to the invention can contain the at least one unsaturated fatty acid in a weight-based amount in the range from 0.1% by weight to 10% by weight, in particular in the range from 0.5% by weight to 8% by weight. -%, preferably in the range from 1% by weight to 5% by weight, based on the composition.
  • the (eye) health-promoting properties of the composition according to the invention can be increased again.
  • the composition according to the invention can also contain astaxanthin.
  • the composition can contain astaxanthin in an amount by weight in the range from 0.1% by weight to 30% by weight, in particular in the range from 0.5% by weight to 20% by weight, preferably in the range from 1 % by weight to 10% by weight, based on the composition.
  • the astaxanthin can be present in its pure form or in the form of a derivative.
  • Astaxanthin is, in particular, a natural carotenoid obtained, for example, from algae.
  • astaxanthin can be said to have a positive effect on improving the situation with tired or irritated eyes. Astaxanthin can also improve visual acuity and the ability of the eye to focus.
  • the additional carotenoid, in particular astaxanthin provides further oxidative protection.
  • the composition according to the invention contains at least one anthocyanin.
  • the composition can contain the at least one anthocyanin, in particular each and/or independently of one another, in an amount by weight in the range from 0.1% by weight to 20% by weight, in particular in the range from 0.2% by weight to 15% by weight, preferably in the range from 0.5% by weight to 10% by weight, based on the composition.
  • the at least one anthocyanin can be present, in particular independently of one another, in pure form or in the form of a derivative.
  • twilight vision for example, can be positively influenced or improved based on the composition according to the invention.
  • composition according to the invention can contain at least one further active ingredient or ingredient, in particular selected from the group of trace elements, minerals, micronutrients and antioxidants and combinations thereof.
  • composition can also contain at least one common or physiologically harmless carrier and/or matrix substance, in particular pharmaceutical or food technology carrier or matrix substance, preferably selected from the group of sugars, starch, cellulose, cellulose derivatives and sugar substitutes and mixtures and combinations thereof.
  • pharmaceutical or food technology carrier or matrix substance preferably selected from the group of sugars, starch, cellulose, cellulose derivatives and sugar substitutes and mixtures and combinations thereof.
  • Such carrier substances or matrix substances can be used in solid form, for example, for the purpose of forming the composition according to the invention.
  • the composition according to the invention contains the combination of (a) lutein and (b) zeaxanthin together with at least one physiologically harmless carrier (excipient) or that the combination of (a) lutein and (b ) Zeaxanthin is used together with at least one physiologically harmless carrier (excipient).
  • composition can contain at least one common additive or auxiliary, in particular pharmaceutical or food technology additive and/or auxiliary, preferably selected from the group of processing aids, stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH Buffer substances, thickeners, flavorings, antiseptics, dyes, buffers, fragrances, fragrances, extenders, binding agents, wetting agents and preservatives as well as their mixtures or combinations.
  • processing aids stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH Buffer substances, thickeners, flavorings, antiseptics, dyes, buffers, fragrances, fragrances, extenders, binding agents, wetting agents and preservatives as well as their mixtures or combinations.
  • composition according to the invention can be in numerous (administration) forms:
  • composition according to the invention can be designed for (per-)oral administration.
  • the composition according to the invention can be designed as a dosage form (application form), in particular as an oral dosage form (application form), or can be a component of such a dosage form (application form).
  • composition according to the invention can be solid or liquid, in particular gel-like or pasty.
  • the composition can also be in the form of a solubilisate.
  • composition according to the invention can be in the form of a solid or liquid dosage form (application form), preferably an oral solid or liquid dosage form (application form), or can be a component of such a dosage form (application form).
  • the composition according to the invention can be in the form of a solid or liquid dosage form (application form) or can be a component of such a dosage form (application form) or the composition can be in the form of a dosage form in the form of a tablet, pill, capsule, particularly preferably soft capsule, hard candy, a granulate, dragee, powder, pellet or the like, preferably tablet or capsule, preferably a capsule, particularly preferably a soft capsule, such as a (soft) gel capsule, and/or be a component of such a dosage form (application form).
  • the dosage form preferably the tablet or capsule, preferably capsule, particularly preferably soft capsule, may have a total weight in the range from 0.01 g to 5 g, in particular in the range from 0.05 g to 4 g, preferably in the range from 0.075 g to 3 g, preferably in the range from 0.1 g to 2 g.
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range of 0.1 mg to 1,000 mg , in particular in the range from 0.2 mg to 500 mg, preferably in the range from 0.5 mg to 300 mg, preferably in the range from 1 mg to 100 mg, particularly preferably in the range from 1.5 mg to 75 mg, very particularly preferably in the range from 2 mg to 50 mg.
  • the composition according to the invention can behave in such a way that the dosage form, in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, contains the combination of (a) lutein and (b) zeaxanthin in one Amount in the range from 0.1 mg to 1,000 mg, in particular in the range from 0.2 mg to 500 mg, preferably in the range from 0.5 mg to 300 mg, preferably in the range from 1 mg to 100 mg, particularly preferably in the range from 1.5 mg to 75 mg, most preferably in the range from 2 mg to 50 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/lutein
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, can contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 0.1 mg to 1,000 mg ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, can contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 0.2 mg to 500 mg ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, can contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 0.5 mg to 300 mg ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, entirely particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, contains the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 1 mg to Contains 100 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1
  • the dosage form may contain the combination of (a) lutein and (b) zeaxanthin in an amount ranging from 1.5 mg to 75 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly particularly
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, contains the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 2 mg to Contains 50 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9.75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 0.1 mg to 1,000 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1:4 to 1:9.75.
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may contain the combination of (a) lutein and (b) zeaxanthin in an amount ranging from 0.2 mg to 500 mg ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:2; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1:4 to 1:9.
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, can contain the combination of (a) lutein and (b) contain zeaxanthin in an amount ranging from 0.5 mg to 300 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:3; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1:5 to 1:9.
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may further contain the combination of (a) lutein and (b) zeaxanthin in an amount ranging from 1 mg to 100 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:4; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio of 1:5.5 to 1:9.
  • the dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range from 1.5 mg to 75 mg ; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:5; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1:6 to 1:8.99.
  • dosage form in particular solid or liquid dosage form, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, may contain the combination of (a) lutein and (b) zeaxanthin in an amount in the range of 2 mg to 50 mg; and wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:6; and/or wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio in the range of 1:6 to 1:8.8.
  • the composition in particular the ingredients and/or active ingredients of the composition, is or is present in spatially separate and functionally related components, in particular at least two spatially separate and functionally related components and/or is or are divided.
  • the at least one component has the combination of (a) lutein and (b) zeaxanthin or that at least one further component has at least one further active ingredient and/or ingredient, in particular as defined above , having.
  • the composition is present or designed in the form of a kit (kit-of-parts).
  • the composition according to the invention is designed as a component of a kit (kit-of-parts) or is a component of a kit (kit-of-parts).
  • the kit (kit-of-parts) can have spatially separate and functionally related components, in particular at least two spatially separate and functionally related components, wherein the composition forms at least one of the aforementioned components, preferably one of the aforementioned components, or its component is.
  • at least one further component and/or at least one component different from the aforementioned component has at least one further active ingredient and/or ingredient, in particular as previously defined.
  • the composition according to the invention can be present or designed as a kit (kit-of-parts).
  • the blue light in particular has a wavelength in the range from 380 nm to 500 nm, in particular in the range from 390 nm to 480 nm, preferably in the range from 400 nm to 470 nm, preferably in the range from 405 nm to 460 nm, particularly preferably in Range from 410 nm to 460 nm, more preferably in the range from 410 nm to 455 nm, even more preferably in the range from 410 nm to 450 nm.
  • the greatest potential for damage to the eye occurs, particularly in a wavelength range of 410 nm to 450 nm. Accordingly, the composition according to the invention has a particularly high protective function.
  • the blue light in particular can also be HEV light (high energy visible light), in particular with a wavelength in the range from 400 nm to 460 nm, preferably in the range from 405 nm to 460 nm, particularly preferably in the range from 405 nm to 455 nm, more preferably in the range from 410 nm to 455 nm, even more preferably in the range from 410 nm to 450 nm.
  • HEV light high energy visible light
  • the blue light in particular can also be LED light (light emitting diode light) or in particular come from or be emitted from an LED light source, preferably an LED lamp, or in particular from one in particular at least one LED light source having display device (display), preferably television, computer, mobile phone or cell phone, laptop and / or tablet display device (display), come from or be emitted from it.
  • the LED light can have a wavelength in the range from 440 nm to 460 nm, in particular approximately 450 nm.
  • a protective function against LED light or light from display devices or displays is made possible in particular, which have an LED light source, in particular for generating light or images.
  • the composition according to the invention can be present in numerous forms.
  • the composition can be used, for example, as a dietary supplement; Drug; pharmaceutical; pharmaceutical composition; medical device; homeopathic; Diet or food is present.
  • the composition can also be present as a cosmetic or consumer item.
  • the composition according to the invention is particularly suitable for use in the prophylactic and/or therapeutic medical treatment of diseases and/or irritations and/or disorders and/or damage to the human eye caused by and/or related to blue light in particular.
  • composition according to the invention is suitable for use in the prophylactic and/or therapeutic medical treatment of sleep disorders caused by and/or related to blue light in particular, in particular difficulty falling asleep and/or staying asleep, and/or of sleep disorders in particular caused by blue light caused and/or related dysregulation of the natural day/night rhythm and/or the circadian rhythm, in particular where the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm are associated with a reduced and/or or inhibited production and/or a reduced and/or inhibited release of melatonin in particular in the human body (i.e. in particular of the body's own melatonin) and/or are caused by this.
  • the reduction or inhibition of the release or production of the body's own melatonin is caused by or is related to exposure to blue light in particular.
  • the disease and/or irritation and/or disorder is a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis , preferably photoretinitis.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retina, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retina, in particular a preferably photochemical damage to the retina Retina, his.
  • the disease and/or irritation and/or disorder may be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or Disruption of the retinal pigment epithelium, in particular a preferably photochemical damage to the retinal pigment epithelium.
  • composition according to the invention can in particular be present as a drug, pharmaceutical and/or pharmaceutical composition.
  • the present invention also relates to a drug, pharmaceutical, medical device or homeopathic, wherein the drug, pharmaceutical, medical device or homeopathic contains or consists of the composition according to the invention, as defined above.
  • the present invention also relates to a dietary supplement, wherein the dietary supplement contains or consists of the composition according to the invention, as defined above.
  • the present invention also relates to a dosage form (application form), in particular solid or liquid dosage form, preferably oral solid or liquid dosage form, preferably in the form of a tablet, pill, capsule, particularly preferably soft capsule, hard caramel, granules, dragees, Powder, pellets or the like, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, the dosage form containing the composition according to the invention, as defined above, optionally together with at least one physiologically harmless carrier (excipient), or consisting thereof.
  • the dosage form can be in the form of a (soft) gel capsule.
  • the present invention therefore also relates to a dosage form (application form), such as a tablet, pill, capsule, particularly preferably soft capsule, hard caramel, a granulate, dragee, powder, pellet or the like, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, wherein the dosage form is the composition according to the invention zung, as defined above, optionally together with at least one physiologically harmless carrier (excipient), or consists of this.
  • a dosage form such as a tablet, pill, capsule, particularly preferably soft capsule, hard caramel, a granulate, dragee, powder, pellet or the like, preferably tablet or capsule, preferably capsule, particularly preferably soft capsule, wherein the dosage form is the composition according to the invention zung, as defined above, optionally together with at least one physiologically harmless carrier (excipient), or consists of this.
  • a further subject of the present invention - according to a second aspect of the present invention - is also the composition according to the invention, in particular as defined above, for use in the prophylactic and / or therapeutic medical treatment of diseases caused by, in particular, blue light and / or related thereto and/or irritation and/or disorders and/or damage to the human eye, the composition having a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, wherein the combination of (a) lutein and (b) zeaxanthin have a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the disease and/or irritation and/or disorder can be a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis, preferably photoretinitis.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retina, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retina, in particular a preferably photochemical damage to the retina Retina, his.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retinal pigment epithelium, in particular a preferably photochemical one Damage to the retinal pigment epithelium.
  • the composition is in particular in the form of a drug, pharmaceutical and/or pharmaceutical composition.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6 , exhibit.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5 .5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1:8.8.
  • a particularly high level of protection can be provided.
  • the present invention also relates to the use of a composition, in particular as defined above, (for the production of a medicament) for the prophylactic and/or therapeutic medical treatment of diseases caused by and/or related to blue light in particular and/or Irritation and/or disorders and/or damage to the human eye, the composition having a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, the combination of (a) Lutein and (b) zeaxanthin have a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the present invention also relates to a composition, in particular as defined above, for use in the prophylactic and/or therapeutic medical treatment of sleep disorders caused by and/or related to blue light in particular, in particular sleep disturbances and/or Disorders of sleeping through the night, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular the sleep disorders and/or the dysregulation of the natural day/night rhythm and /or the circadian rhythm is accompanied and/or caused by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, especially in the human body (ie in particular of the body's own melatonin), wherein the composition has a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zea
  • the reduction or inhibition of the release or production of the body's own melatonin in particular is caused by and/or is related to blue light in particular.
  • the present invention also relates to the use of a composition, in particular as defined above, (for the production of a medicament) for the prophylactic and/or therapeutic medical treatment of sleep disorders caused by and/or related to blue light, in particular - and/or difficulty sleeping through the night, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular whereby the sleep disorders and/or the dysregulation of the natural day/night rhythm Night rhythm and/or the circadian rhythm are accompanied and/or caused by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body (i.e.
  • the Composition has a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, wherein the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1: 1, in particular in the range from 1: 4 to 1: 9.75.
  • the present invention also relates to the drug, pharmaceutical, medical device or homeopathic, as defined above, or dosage form, as defined above, each for use in the prophylactic and / or therapeutic medical treatment of and / or caused by, in particular, blue light. or related diseases and/or irritations and/or disorders and/or damage to the human eye.
  • the present invention according to the present aspect also relates to the use of the drug, pharmaceutical, medical device or homeopathic, as defined above, or the dosage form as defined above, in each case (for the production of a medicament) for the prophylactic and / or therapeutic medical treatment of Diseases and/or irritations and/or disorders and/or damage to the human eye caused by and/or related to blue light in particular.
  • the present invention also relates to the drug, pharmaceutical, medical device or homeopathic as defined above, or the dosage form as defined above, each for use in the prophylactic and/or therapeutic medical treatment of and/or caused by, in particular, blue light. or related sleep disorders, in particular difficulty falling asleep and/or staying asleep, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm is accompanied by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body (i.e. in particular of the body's own melatonin). and/or caused by this.
  • the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm is accompanied by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly
  • the present invention also relates, according to the present aspect, to the use of the drug, pharmaceutical, medical device or homeopathic, as defined above, or the dosage form as defined above, in each case (for the production of a medicament) for the prophylactic and / or therapeutic medical treatment of
  • sleep disorders caused by and/or related to blue light, in particular problems falling asleep and/or staying asleep, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by and/or related to blue light in particular Rhythm, in particular whereby the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm with a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin in particular in the human body (ie in particular of the body's own melatonin) and/or caused by this.
  • Another subject of the present invention - according to a third aspect of the present invention - is the combination of (a) lutein and (b) zeaxanthin, in particular pharmaceutical combination of (a) lutein and (b) zeaxanthin, for use in prophylactic and /or therapeutic medical treatment of diseases and/or irritations and/or disorders and/or damage to the human eye caused by, in particular, blue light and/or related thereto, the combination of (a) lutein and (b) zeaxanthin being a lutein / zeaxanthin weight ratio ⁇ 1: 1, in particular in the range from 1: 4 to 1: 9.75.
  • the disease and/or irritation and/or disorder may be a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis, preferably photoretinitis, and wherein the disease and/or irritation and/or disorder may be a Lesion and / or disorder of the retina, in particular a (blue) light-induced and / or photochemical and / or non-thermal lesion and / or disorder of the retina, in particular a preferably photochemical damage to the retina.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retinal pigment epithelium, in particular a preferably photochemical one Damage to the retinal pigment epithelium.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1: 6, have.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio in the range of 1:4 to 1:9, preferably in the range of 1:5 to 1:9, preferably in the range of 1:5 .5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1:8.8.
  • the present invention also relates to the use of a combination of (a) lutein and (b) zeaxanthin, in particular a pharmaceutical combination of (a) lutein and (b) zeaxanthin, (for the production of a medicament) for prophylactic and/or therapeutic medical treatment of diseases and/or irritations and/or disorders and/or damage to the human eye caused by, in particular, blue light and/or related thereto, the combination of (a) lutein and (b) zeaxanthin being a lutein/zeaxanthin - Weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the disease and/or irritation and/or disorder can be a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis, preferably photoretinitis.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retina, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retina, in particular a preferably photochemical damage to the Retina, his.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retinal pigment epithelium, in particular a preferably photochemical one Damage to the retinal pigment epithelium.
  • composition can in particular be in the form of a drug, pharmaceutical and/or pharmaceutical composition.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6 , exhibit.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio in the range of 1:4 to 1:9, preferably in the range of 1:5 to 1:9, preferably in the range of 1:5 .5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1:8.8.
  • the present invention also relates to the combination of (a) lutein and (b) zeaxanthin, in particular pharmaceutical combination of (a) lutein and (b) zeaxanthin, for use in the prophylactic and / or therapeutic medical treatment of in particular Sleep disorders caused by and/or related to blue light, in particular problems falling asleep and/or staying asleep, and/or dysregulation of the natural day/night rhythm and/or circadian rhythm caused by and/or related to blue light in particular , in particular wherein the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm are associated with a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body (i.e.
  • the present invention also relates to the use of a combination of (a) lutein and (b) zeaxanthin, in particular a pharmaceutical combination of (a) lutein and (b) zeaxanthin, (for the production of a medicament) for prophylactic and/or or therapeutic medical treatment of sleep disorders caused by and/or related to blue light, in particular problems falling asleep and/or staying asleep, and/or of dysregulation of the natural day/night cycle caused by and/or related to blue light in particular.
  • Rhythm and/or the circadian rhythm in particular wherein the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm with a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin especially in the human body (i.e. especially from the body's own melatonin) accompanied and/or caused by this, the combination of (a) lutein and (b) zeaxanthin having a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • a further subject of the present invention - according to a fourth aspect of the present invention - is also the use of a composition, in particular as defined above, for the non-medical treatment, in particular for the prophylactic non-medical treatment, of diseases caused by and/or related to blue light in particular and/or irritation and/or disorders and/or damage to the human eye, the composition having a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, wherein the combination of (a) lutein and (b) zeaxanthin have a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the disease and/or irritation and/or disorder can be a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis, preferably photoretinitis.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retina, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retina, in particular a preferably photochemical damage to the Retina, his.
  • the disease and/or irritation and/or disorder can also be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retinal pigment epithelium, in particular a preferably photochemical damage to the retinal pigment epithelium.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1: 6, have.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio in the range of 1:4 to 1:9, preferably in the range of 1:5 to 1:9, preferably in the range of 1:5 .5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, very particularly preferably in the range from 1:6 to 1:8.8.
  • composition according to the invention may in particular be in the form of a nutritional supplement, dietetic or food.
  • the present invention also relates in this context to the use of the nutritional supplement according to the invention, as defined above, or the dosage form according to the invention, as defined above, for non-medical treatment, in particular for prophylactic non-medical treatment, of and/or caused by, in particular, blue light related diseases and/or irritations and/or disorders and/or damage to the human eye.
  • the present invention also relates to the use of the composition according to the invention, in particular as defined above, for the non-medical treatment, in particular for the prophylactic non-medical treatment, of sleep disorders caused by, in particular, blue light and/or related thereto, in particular a and/or difficulty sleeping through the night, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular the sleep disorders and/or the dysregulation of the natural day/night -Rhythm and/or circadian rhythm with a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body (ie, in particular of the body's own melatonin) accompanied and/or caused thereby, the composition having a combination of (a) lutein and (b) zeaxanthin, in particular in effective amounts, preferably in pharmaceutically effective amounts, the combination of (a) lutein and (b) Zea
  • the present invention also relates to the use of the nutritional supplement according to the invention, as defined above, or the dosage form according to the invention, as defined above, for the non-medical treatment, in particular for the prophylactic non-medical treatment, of sleep disorders caused by, in particular, blue light and/or related thereto, in particular, difficulty falling asleep and/or staying asleep, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular the sleep disorders and/or the dysregulation of the natural Day/night rhythm and/or the circadian rhythm are accompanied and/or caused by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body (i.e. in particular of the body's own melatonin).
  • a further subject of the present invention - according to a fifth aspect of the present invention - is the use according to the invention of a combination of (a) lutein and (b) zeaxanthin for the non-medical treatment, in particular for the prophylactic non-medical treatment, of and caused by blue light in particular /or related diseases and/or irritations and/or disorders and/or damage to the human eye, the combination of (a) lutein and (b) zeaxanthin being a Lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the disease and/or irritation and/or disorder may be a retinitis, in particular a (blue) light-induced and/or photochemical and/or non-thermal retinitis, preferably photoretinitis.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retina, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retina, in particular a preferably photochemical damage to the Retina, his.
  • the disease and/or irritation and/or disorder can be a lesion and/or disorder of the retinal pigment epithelium, in particular a (blue) light-induced and/or photochemical and/or non-thermal lesion and/or disorder of the retinal pigment epithelium, in particular a preferably photochemical one Damage to the retinal pigment epithelium.
  • the present invention also relates to the use of a combination of (a) lutein and (b) zeaxanthin for the non-medical treatment, in particular for the prophylactic non-medical treatment, of sleep disorders caused by, in particular, blue light and/or related thereto, in particular A - and/or difficulty sleeping through the night, and/or dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular whereby the sleep disorders and/or the dysregulation of the natural day/night rhythm Night rhythm and/or the circadian rhythm are accompanied and/or caused by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin, particularly in the human body, the combination of (a) lutein and (b) Zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular in the range from 1:4 to 1:9.75.
  • the combination of (a) lutein and (b) zeaxanthin has a lutein/zeaxanthin weight ratio ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6, or that the combination of (a) lutein and (b) zeaxanthin Lutein/zeaxanthin weight ratio in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1:8.99, most preferably in the range from 1:6 to 1:8.8.
  • Another subject of the present invention - according to a sixth aspect of the present invention - is the method according to the invention for the prophylactic and / or therapeutic medical treatment of diseases and / or irritations and / or disorders caused by, in particular, blue light and / or related thereto and/or damage to the human eye, wherein in the method a patient having and/or suffering from the diseases and/or irritations and/or disorders and/or damages to the human eye is given a pharmaceutically effective and/or therapeutically effective amount of the composition according to the Invention, as defined above, or the drug, pharmaceutical, medical device or homeopathic according to the invention, as defined above, or the dosage form according to the invention, as defined above, is administered.
  • the present invention also relates to the method according to the invention for the prophylactic or therapeutic medical treatment of sleep disorders caused by and/or related to blue light in particular, in particular difficulty falling asleep and/or staying asleep, and/or of sleep disorders in particular caused by blue light
  • Light-induced and/or related dysregulation of the natural day/night rhythm and/or the circadian rhythm in particular where the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm are associated with a reduced and / or inhibited production and / or a reduced and / or inhibited release of melatonin in particular in the human body (ie in particular of the body's own melatonin) are accompanied and / or caused by this
  • the method according to the invention being one of Patients having and/or suffering from sleep disorders and/or dysregulation are given a pharmaceutically effective and/or therapeutically effective amount of the composition according to the invention, as defined above, or of the drug, pharmaceutical, medical device or homeopathic, as defined above, or the dosage
  • Another subject of the present invention - according to a seventh aspect of the present invention - is the method for non-medical treatment, in particular for prophylactic non-medical treatment, of diseases and/or irritations and/or diseases caused by, in particular, blue light and/or related thereto Disorders and/or damage to the human eye, wherein in the method a patient who has and/or suffers from the diseases and/or irritations and/or disorders and/or damage to the human eye is given a food-technically effective and/or food-technically relevant amount of the composition of the invention as defined above, or the nutritional supplement as defined above, or the dosage form as defined above.
  • the present invention also relates to the method according to the invention for the non-medical treatment, in particular for the prophylactic non-medical treatment, of sleep disorders caused by and/or related to blue light, in particular difficulties falling asleep and/or staying asleep, and/or of dysregulation of the natural day/night rhythm and/or the circadian rhythm caused by blue light in particular and/or related thereto, in particular where the sleep disorders and/or the dysregulation of the natural day/night rhythm and/or the circadian rhythm associated with and/or caused by a reduced and/or inhibited production and/or a reduced and/or inhibited release of melatonin in particular in the human body (ie in particular of the body's own melatonin), with the method causing sleep disorders and/or dysregulation having and/or patients suffering from this are administered a food-technically effective and/or food-technically relevant amount of the composition according to the invention, as previously defined, or of the nutritional supplement according to the invention, as previously defined, or of the dosage form according to
  • kits (kit-of-parts) comprises spatially separate and functionally related components, in particular at least two spatially has separate and functionally related components; wherein at least one of the aforementioned components, preferably one of the aforementioned components, has or consists of the composition according to the invention, in particular as defined above; in particular, wherein the at least one further component and/or at least one component different from the aforementioned component has or consists of at least one further active ingredient and/or ingredient, as defined above.
  • the combination of (a) lutein and (b) zeaxanthin can have a lutein/zeaxanthin weight ratio ⁇ 1:1, in particular ⁇ 1:2, preferably ⁇ 1:3, preferably ⁇ 1:4, particularly preferably ⁇ 1:5, very particularly preferably ⁇ 1:6.
  • the combination of (a) lutein and (b) zeaxanthin has a lutein / zeaxanthin weight ratio in the range from 1: 4 to 1: 9, 75, in particular in the range from 1:4 to 1:9, preferably in the range from 1:5 to 1:9, preferably in the range from 1:5.5 to 1:9, particularly preferably in the range from 1:6 to 1 : 8.99, most preferably in the range from 1: 6 to 1: 8.8.
  • the lutein can be present as a pure substance and/or in the form of its esters, salts and/or hydrates, preferably esters.
  • the lutein is preferably present as a pure substance.
  • the zeaxanthin can be present as a pure substance and/or in the form of its esters, salts and/or hydrates, preferably esters.
  • the zeaxanthin can be present as a pure substance.
  • the zeaxanthin is in the form of its isomers, in particular in the form of a mixture of at least two isomers, preferably in the form of (3R, 3'R)-zeaxanthin, (3S, 3'S)-zeaxanthin and/or meso-zeaxanthin, preferably (3R, 3'R)-zeaxanthin and/or meso-zeaxanthin, is present.
  • the blue light in particular, has a wavelength in the range from 380 nm to 500 nm, in particular in the range from 390 nm to 480 nm, preferably in the range from 400 nm to 470 nm, preferably in the range from 405 nm to 460 nm, particularly preferably in the range from 410 nm to 460 nm, more preferably in the range from 410 nm to 455 nm, even more preferably in the range from 410 nm to 450 nm , having.
  • the blue light in particular can be HEV light (high energy visible light), in particular with a wavelength in the range from 400 nm to 460 nm, preferably in the range from 405 nm to 460 nm, particularly preferably in the range from 405 nm to 455 nm, more preferably in the range from 410 nm to 455 nm, even more preferably in the range from 410 nm to 450 nm.
  • HEV light high energy visible light
  • the blue light in particular can be LED light (Light Emitting D/ode light) or in particular from one LED light source, preferably an LED light source, comes from and/or is emitted therefrom and/or in particular from a display device (display) which in particular has an LED light source, preferably a television, computer, mobile phone or cell phone, laptop. and/or tablet display device (display), come from or be emitted from it.
  • LED light Light Emitting D/ode light
  • a display device which in particular has an LED light source, preferably a television, computer, mobile phone or cell phone, laptop. and/or tablet display device (display), come from or be emitted from it.
  • Fig. 1 is a graphical representation in the form of a curve diagram illustrating the absorption behavior depending on the wavelength of the irradiated light for various compositions based on lutein/zeaxanthin solutions, the respective compositions each having specific and different lutein/zeaxanthin weight ratios (see also the following statements); the 2 and 3 are shown as an enlarged detail;
  • FIG. 1A shows an enlarged detail according to the marking A of FIG. 1 with the further illustration of the absorption behavior of the compositions examined, each with specific lutein/zeaxanthin weight ratios for a specific wavelength range of the irradiated (blue) light
  • Fig. 1 B shows a further enlargement of the detail according to the marking B of Fig. 1 with the further illustration of the absorption behavior of the compositions examined, each with specific lutein/zeaxanthin weight ratios for a further specific wavelength range of the irradiated (blue) light, such as in particular the area corresponds to the maximum blue light content of LED light sources.
  • LED light sources or LED lamps also produce stronger radiation in the wavelength range of blue light than, for example, conventional light bulbs.
  • a narrow wavelength range of the light spectrum namely in particular in a wavelength range around 450 nm, there can be an even greater potential for damage to the eyes or eye health, with this range often being emitted to an increased extent by LED light sources.
  • compositions with a defined lutein/zeaxanthin weight ratio i.e. with a higher proportion of zeaxanthin according to the invention compared to lutein
  • absorption properties in particular blue light, in a defined wavelength range.
  • this leads to improved protection against this light and an improvement in eye health.
  • compositions M1 to M6 compositions M1 to M6 based on solutions of lutein and zeaxanthin, each with a defined lutein/zeaxanthin weight ratio, with measurements of the intensity of the light after passing through of the light can be carried out using a cuvette with the appropriate composition or test solution.
  • compositions are prepared in the form of solutions or based on the use of a solvent with the following specified lutein/zeaxanthin weight ratios (with identical total amount or concentration of the carotenoids lutein and zeaxanthin in solution) using a solvent (cf. Tabel).
  • the composition M1 has a lutein/zeaxanthin weight ratio of 13:1; the composition M2 has a lutein/zeaxanthin weight ratio of 5:1; the composition M3 has a lutein/zeaxanthin weight ratio of 1:1; the composition M4 has a lutein/zeaxanthin weight ratio of 1:3; the composition M5 has a lutein/zeaxanthin weight ratio of 1:6; and finally the composition M6 has a lutein/zeaxanthin weight ratio of 1:9.
  • Fig. 1 shows the absorption behavior of the different compositions M1 to M6 depending on the wavelength of the irradiated light. It turns out that in the blue light range, the compositions M5 and M6 with the highest proportions of zeaxanthin have comparable and overall very high absorption powers or very high absorptions.
  • compositions with the highest proportions of zeaxanthin and thus the compositions M5 and M6 have particularly good absorption properties, as shown by the high absorption values explained.
  • the compositions with the highest proportions of zeaxanthin namely the compositions M5 and M6, in particular also for the special wavelength range of blue light around 450 nm (and thus in the range of LED light).
  • the greatest potential for damage to the eye has excellent absorption properties, so that the greatest protection against blue light, especially in the wavelength range mentioned, results in this regard.
  • compositions M5 and M6 according to the invention show the excellent and improved absorption behavior of the compositions M5 and M6 according to the invention in question with the special lutein/zeaxanthin weight ratio, according to which significantly improved absorption properties in the blue light range are achieved for correspondingly high values or proportions of zeaxanthin .
  • This shows the excellent protective function of these compositions against, in particular, blue light and in particular against light coming from LED light sources with the special blue light component in this regard, as mentioned above.
  • the corresponding compositions also enable a high protective effect against blue light from, in particular, LED-based display devices or displays.
  • the protective effect extends to reducing the negative influence of blue light both directly on eye health and on sleep behavior and the day/night rhythm.
  • compositions M5 and M6 show the greatest absorption of blue light in the present wavelength range (cf. compositions M5 and M6 according to the invention).
  • the studies show that the absorption found, particularly in the aforementioned wavelength ranges of blue light, is significantly greater compared to compositions that contain a higher proportion of lutein. Consequently, the compositions according to the invention with a correspondingly large proportion of zeaxanthin enable an excellent protective function both in the area of blue light as a whole and specifically in the area of the particularly critical LED blue light.
  • the compositions M5 and M6 have excellent properties in this regard. On this basis, an optimal protective effect can be provided, as stated above.
  • the active ingredients in the form of lutein and zeaxanthin are applied in a corresponding manner in the eye or in the retina and thus directly on the are present at the site of action or are accumulated there, so that the corresponding protective effect can be provided on this basis, namely as a result of or accompanied by the improved absorption of blue light (so that, according to the invention, a cause-related effect is made possible)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne le domaine de l'influence négative ou de l'effet négatif, en particulier, de la lumière bleue sur la santé oculaire, notamment par rapport à l'œil humain, ainsi que sur le comportement du sommeil ou le rythme jour/nuit, ainsi qu'une composition correspondante et son utilisation.
PCT/EP2023/056569 2022-04-01 2023-03-15 Composition de protection de l'œil WO2023186536A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23712476.3A EP4432857A1 (fr) 2022-04-01 2023-03-15 Composition de protection de l'oeil

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102022107884.1 2022-04-01
DE102022107884 2022-04-01
DE102022110581.4 2022-04-29
DE102022110581.4A DE102022110581A1 (de) 2022-04-01 2022-04-29 Zusammensetzung zum Schutz des Auges

Publications (1)

Publication Number Publication Date
WO2023186536A1 true WO2023186536A1 (fr) 2023-10-05

Family

ID=85724703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/056569 WO2023186536A1 (fr) 2022-04-01 2023-03-15 Composition de protection de l'œil

Country Status (2)

Country Link
EP (1) EP4432857A1 (fr)
WO (1) WO2023186536A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
WO2003063848A1 (fr) * 2002-01-30 2003-08-07 Dsm Ip Assets B.V. Luteine/zeaxanthine servant a la protection contre l'eblouissement
EP2138055A1 (fr) * 2008-06-02 2009-12-30 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Formule d'aliment bénéfique pour la persistance de visuognosis et utilisation associée
WO2013041935A1 (fr) 2011-09-19 2013-03-28 Omniactive Health Technologies Limited Procédé efficace de préparation d'une oléorésine contenant du lycopène et cristaux de lycopène destinés à une consommation humaine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
WO2003063848A1 (fr) * 2002-01-30 2003-08-07 Dsm Ip Assets B.V. Luteine/zeaxanthine servant a la protection contre l'eblouissement
EP2138055A1 (fr) * 2008-06-02 2009-12-30 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Formule d'aliment bénéfique pour la persistance de visuognosis et utilisation associée
WO2013041935A1 (fr) 2011-09-19 2013-03-28 Omniactive Health Technologies Limited Procédé efficace de préparation d'une oléorésine contenant du lycopène et cristaux de lycopène destinés à une consommation humaine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"RÖMPP Chemie Lexikon", vol. 6, 1999, GEORG THIEME VERLAG, pages: 5037 - 2460
ARUNKUMAR RANGANATHAN ET AL: "What do we know about the macular pigment in AMD: the past, the present, and the future", EYE, NATURE PUBLISHING GROUP, GB, vol. 32, no. 5, 26 March 2018 (2018-03-26), pages 992 - 1004, XP036619342, ISSN: 0950-222X, [retrieved on 20180326], DOI: 10.1038/S41433-018-0044-0 *

Also Published As

Publication number Publication date
EP4432857A1 (fr) 2024-09-25

Similar Documents

Publication Publication Date Title
DE60032778T2 (de) Zusammensetzungen für stabile Karotin-Xanthophyl enthaltende Kapseln und Methoden zum Gebrauch
DE60201824T2 (de) Nahrungsergänzung zur behandlung von makuladegeneration
DE60318390T2 (de) Lutein/zeaxanthin gegen blendung
DE69636951T2 (de) Pharmazeutisch aktive karotenoide
DE212013000066U1 (de) Krillöl und reagierte Astaxanthinzusammensetzung
DE202010017991U1 (de) Eierschalmembranformulierungen zur Linderung von Gelenkschmerzen
CN109845868A (zh) 一种改善视疲劳的叶黄素酯压片糖果及其制备方法
CN109939058A (zh) 一种防蓝光的化妆品组合物及其制备方法
DE202010018076U1 (de) Zusammensetzung und deren Verwendung zum Verzögern und Verbessern einer photoinduzierten Netzhautschädigung und von Katarakten unter Verbesserung eines Xerophthalmiesyndroms
CN106617055A (zh) 一种改善退化性眼疾的护眼保健食品及其制备方法
DE202011110413U1 (de) Zusammensetzung zum Verzögern und Verbessern einer photoinduzierten Netzhautschädigungund von Katarakten unter Verbesserung eines Xerophthalmiesyndroms unter Verwendung vonOmega-Cholin
DE212015000031U1 (de) Zusammensetzung, die Samenölextrakte und Phospholipide verwendet, um die Absorption von Carotinoiden zu verbessern
AT406935B (de) Verfahren zur herstellung eines öligen präparates
CN104382003A (zh) 一种叶黄素越橘软胶囊及其制备方法
EP1210073B1 (fr) Substance de protection solaire a administration orale
DE102009038565A1 (de) Astaxanthin
DE202005012984U1 (de) Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
WO2023186536A1 (fr) Composition de protection de l'œil
DE19733892C2 (de) Bestrahlungsschutz-Verfahren
DE202022102350U1 (de) Zusammensetzung zum Schutz des Auges
DE202023001615U1 (de) Zusammensetzung zur Verbesserung und Unterstützung der Augengesundheit
EP1616490A1 (fr) Composition comprenant de la lutéine, du zinc et du cuivre
DE202013005637U1 (de) Mittel mit Tocotrienol bei Verbrennungen durch Sonne, radioaktive Strahlung oder Hitze
EP2269649A2 (fr) Compositions contenant un system actif capillaire a differentiabilite d'application et utilisation
WO2005063051A1 (fr) Produit de combinaison de micronutriments adapte au regime bilan complementaire dans le cadre de la degenerescence maculaire liee a l'age

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23712476

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023712476

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023712476

Country of ref document: EP

Effective date: 20240619